CSL’s growth slowed, and its premium valuation reset hard. The post What on earth's going on with CSL shares? appeared first ...
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, has released its first Corporate Responsibility Report, combining information about the Company’s economic, social and ...
CSL ( (AU:CSL)) has provided an update. CSL Limited has reported the latest daily progress of its on-market share buy-back program for its ordinary fully paid shares. The company disclosed that it has ...
CSL Limited has provided an updated notification to the ASX regarding its ongoing on-market share buy-back of ordinary fully paid shares. The update reflects the latest daily activity under the ...
Hosted on MSN
CSL Limited updates on daily buy-back progress
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
After a sharp decline, CSL is in a new phase. The question is what happens next. The post How much would $10,000 become if CSL shares returned to their record high? appeared first on The Motley Fool ...
NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited (CSLLY). CSL Limited is a ...
The biotech's shares have had a tough run, but the long-term story may not be broken. The post Could the CSL share price ...
Hello. I'm Fiona Mead, CSL's Company Secretary. Thank you for joining us for the first session of CSL's 2025 Capital Markets event. Our presentation tonight will start with some remarks from CSL's CEO ...
Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results